Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients.

CONCLUSIONS: Crizotinib leads to a clinical response in patients with MET rearrangements. Our functional analyses together with the clinical data suggest that these structural alterations may represent actionable targets in lung cancer patients. PMID: 29284707 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29284707?dopt=Abstract

Source: Clinical Cancer Research - December 28, 2017 Category: Cancer & Oncology Authors: Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller JN, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heuka Tags: Clin Cancer Res Source Type: research